Prescription medicine
Galcanezumab Brand names: Emgality
Galcanezumab (Emgality) is a prescription medicine. No generic is listed; pharmacies paid $734.28 per mL (Emgality 120 mg/mL pen) in the October 7, 2026 NADAC survey.
- No generic listed
Check it at the source: the galcanezumab FDA label on DailyMed (effective June 5, 2026); every galcanezumab label on DailyMed.
Highlights of the record
FDA label of June 5, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageEMGALITY ® is a calcitonin-gene related peptide antagonist indicated in adults for the: preventive treatment of migraine.
Forms and strengths
- 100 mg/ml
- 120 mg/ml
Injection (solution).
On the market
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $734.28 per mL Emgality 120 mg/mL pen
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 31,311 through July 30, 2026
What is galcanezumab used for?
From the label: indications and usageEMGALITY ® is a calcitonin-gene related peptide antagonist indicated in adults for the: preventive treatment of migraine. ( 1.1 ) treatment of episodic cluster headache. ( 1.2 ) 1.1 Migraine EMGALITY is indicated for the preventive treatment of migraine in adults. 1.2 Episodic Cluster Headache EMGALITY is indicated for the treatment of episodic cluster headache in adults.
Conditions named in the indications of galcanezumab's FDA labels, with every medicine labeled for each:
Source: FDA drug label (EMGALITY), Eli Lilly and Company, effective June 5, 2026 (SPL set 33a147be-233a-40e8-a55e-e40936e28db0), via openFDA; the full label on DailyMed
Is there a generic for galcanezumab (Emgality)?
No generic galcanezumab is approved (Drugs@FDA, October 8, 2026).
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for galcanezumab (Emgality)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $734.28 per mL (Emgality 120 mg/mL pen), up 3% from $713.83 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Emgality 300 mg dose (100 mg/mL x 3 syringes) (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Emgality 120 mg/mL pen | Brand | $734.28 per mL | n/a | +3% |
| Emgality 120 mg/mL syringe | Brand | $734.42 per mL | n/a | +3% |
| Emgality 300 mg dose (100 mg/mL x 3 syringes) | Brand | $612.52 per mL | n/a | +3% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What do FAERS reports show for galcanezumab?
The FDA Adverse Event Reporting System holds 31,311 reports that list galcanezumab among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 85 are coded as a death and 1,122 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as galcanezumab?
4 other medicines are given the same way (subcutaneous) and in the same FDA class as galcanezumab or labeled mainly for the same use (migraine), the same class first. Migraine lists all 27 medicines labeled for it, by any route. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (subcutaneous) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Sumatriptan | Migraine | 20 labelers | $14.93 per mL 6 mg/0.5 mL vial | No current entry |
| Erenumab | Migraine | none listed | $753.33 per mL 140 mg/mL autoinjector | No current entry |
| Fremanezumab | Migraine | none listed | $508.17 per mL 225 mg/1.5 mL autoinject | No current entry |
| Dihydroergotamine | Migraine | none listed | n/a | No current entry |
Every medicine labeled for the same conditions as galcanezumab
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Alternatives to galcanezumab
- 4 medicines for the same use
- Galcanezumab side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other